Downregulation of microRNA‑497 is associated with upregulation of synuclein γ in patients with osteosarcoma

Wang,Liang; Gao,Hongwei; Gong,Ningji; Gong,Mingzhi

doi:10.3892/etm.2016.3838

Downregulation of microRNA‑497 is associated with upregulation of synuclein γ in patients with osteosarcoma

Authors:
- Liang Wang
- Hongwei Gao
- Ningji Gong
- Mingzhi Gong
View Affiliations

Affiliations: Department of Osteological Surgery, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China, Emergency Department, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China
Published online on: October 26, 2016 https://doi.org/10.3892/etm.2016.3838
Pages: 3761-3766

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effects of microRNA (miRNA/miR)‑497 expression levels on the expression levels of synuclein γ (SNCG) in serum samples, as well as osteosarcoma and lung‑metastatic tissue samples, from patients with osteosarcoma. Between December 2010 and August 2013, fasting peripheral blood was collected from 36 patients with osteosarcoma for serum separation. In addition, osteosarcoma and lung metastatic tissues were resected from 15 osteosarcoma patients with lung metastasis by surgery. Bioinformatics was employed to predict the amount miRNA that binds to SNCG. Reverse transcription‑quantitative polymerase chain reaction was used to determine the expression levels of SNCG and miR‑497, and western blotting was performed to determine protein expression levels. It was observed that SNCG mRNA and protein expression levels were significantly upregulated in osteosarcoma tissues (P<0.01). Additionally, SNCG mRNA (P<0.01) and protein (P<0.05) expression levels were significantly upregulated in the blood of patients with osteosarcoma. SNCG mRNA and protein expression levels were also significantly upregulated in lung metastatic tissues (P<0.01). miR‑497 was significantly downregulated in all three samples; therefore downregulation of miR‑497 may lead to the occurrence, development and metastasis of osteosarcoma through the upregulation of SNCG mRNA. In summary, the upregulation of SNCG in blood, osteosarcoma tissue and lung metastatic tissue samples is associated with the dowregulation of miR‑497, suggesting that miR‑497 may be a potential marker and therapeutic target for the treatment of osteosarcoma.

View Figures

View References

1	Lei P, Xie J, Wang L, Yang X, Dai Z and Hu Y: microRNA-145 inhibits osteosarcoma cell proliferation and invasion by targeting ROCK1. Mol Med Rep. 10:155–160. 2014.PubMed/NCBI
2	Jaffe N: Osteosarcoma: Review of the past, impact on the future. The American experience. Cancer Treat Res. 152:239–262. 2009. View Article : Google Scholar : PubMed/NCBI
3	Ferguson WS and Goorin AM: Current treatment of osteosarcoma. Cancer Invest. 19:292–315. 2001. View Article : Google Scholar : PubMed/NCBI
4	Hameed M and Dorfman H: Primary malignant bone tumours - recent developments. Semin Diagn Pathol. 28:86–101. 2011. View Article : Google Scholar : PubMed/NCBI
5	Li R, Liu J, Wu H, Liu L, Wang L and Zhang S: TIKI2 suppresses growth of osteosarcoma by targeting Wnt/β-catenin pathway. Mol Cell Biochem. 392:109–116. 2014. View Article : Google Scholar : PubMed/NCBI
6	Mao JH, Zhou RP, Peng AF, Liu ZL, Huang SH, Long XH and Shu Y: microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN. Oncol Lett. 4:1125–1129. 2012.PubMed/NCBI
7	Jiang Y, Liu YE, Goldberg ID and Shi YE: Gamma synuclein, a novel heat-shock protein-associated chaperone, stimulates ligand-dependent estrogen receptor alpha signaling and mammary tumorigenesis. Cancer Res. 64:4539–4546. 2004. View Article : Google Scholar : PubMed/NCBI
8	Ji H, Liu YE, Jia T, Wang M, Liu J, Xiao G, Joseph BK, Rosen C and Shi YE: Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res. 57:759–764. 1997.PubMed/NCBI
9	Morgan J, Hoekstra AV, Chapman-Davis E, Hardt JL, Kim JJ and Buttin BM: Synuclein-γ (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma. Gynecol Oncol. 114:293–298. 2009. View Article : Google Scholar : PubMed/NCBI
10	Hibi T, Mori T, Fukuma M, Yamazaki K, Hashiguchi A, Yamada T, Tanabe M, Aiura K, Kawakami T, Ogiwara A, et al: Synuclein-γ is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer. Clin Cancer Res. 15:2864–2871. 2009. View Article : Google Scholar : PubMed/NCBI
11	Han S, She F, Wang D, Yao X, Jiang L and Chen Y: SNCG gene silencing in gallbladder cancer cells inhibits key tumorigenic activities. Front Biosci (Landmark Ed). 17:1589–1598. 2012. View Article : Google Scholar : PubMed/NCBI
12	Pan ZZ, Bruening W, Giasson BI, Lee VM and Godwin AK: Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem. 277:35050–35060. 2002. View Article : Google Scholar : PubMed/NCBI
13	Liu H, Liu W, Wu Y, Zhou Y, Xue R, Luo C, Wang L, Zhao W, Jiang JD and Liu J: Loss of epigenetic control of synuclein-γ gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res. 65:7635–7643. 2005.PubMed/NCBI
14	Dorfman HD, Czemiak B and Kotz R: World Health Organization Classification of TumoursWorld Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CDM, Unni KK and Mertens F: IARC Press; Lyon, France: pp. 227–232. 2002
15	Enneking WF: Staging musculoskeletal tumorsMusculoskeletal Tumor Surgery. Churchill Livingstone; New York: pp. 69–122. 1983
16	Li P, Xie XB, Chen Q, Pang GL, Luo W, Tu JC, Zheng F, Liu SM, Han L, Zhang JK, et al: MiRNA-15a mediates cell cycle arrest and potentiates apoptosis in breast cancer cells by targeting synuclein-gamma. Asian Pac J Cancer Prev. 15:6949–6954. 2014. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Zhou X, Jing J, Peng J, Mao W, Zheng Y, Wang D, Wang X, Liu Z and Zhang X: Expression and clinical significance of galectin-3 in osteosarcoma. Gene. 546:403–407. 2014. View Article : Google Scholar : PubMed/NCBI
19	Shweikeh F, Bukavina L, Saeed K, Sarkis R, Suneja A, Sweiss F and Drazin D: Brain metastasis in bone and soft tissue cancers: A review of incidence, interventions, and outcomes. Sarcoma. 2014:4751752014. View Article : Google Scholar : PubMed/NCBI
20	Link MP, Gebhardt MC and Meyers PA: Chapter 35: OsteosarcomaPrinciples and Practice of Pediatric Oncology. Pizzo PA and Poplack DG: 5th. Lippincott Williams & Wilkins; Philadelphia, PA: pp. 1051–1089. 2006
21	Taheriazam A, Bahador R, Karbasy SH, Jamshidl SM, Torkaman A, Yahaghi E and Shakeri M: Down-regulation of microRNA-26a and up-regulation of microRNA-27a contributes to aggressive progression of osteosarcoma. Diagn Pathol. 10:1662015. View Article : Google Scholar : PubMed/NCBI
22	Wang T, Ji F, Dai Z, Xie Y and Yuan D: Increased expression of microRNA-191 as a potential serum biomarker for diagnosis and prognosis in human osteosarcoma. Cancer Biomark. 15:543–550. 2015. View Article : Google Scholar : PubMed/NCBI
23	Ninkina NN and Bukhman VL: Synucleins - to have or not to have. Genetika. 36:1487–1491. 2000.(In Russian). PubMed/NCBI
24	Guo ST, Jiang CC, Wang GP, Li YP, Wang CY, Guo XY, Yang RH, Feng Y, Wang FH, Tseng HY, et al: MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene. 32:1910–1920. 2012. View Article : Google Scholar : PubMed/NCBI
25	Wang W, Ren F, Wu Q, Jiang D, Li H and Shi H: MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer. Oncol Rep. 32:2127–2133. 2014.PubMed/NCBI
26	Han J, Huo M, Mu M, Liu J and Zhang J: miR-497 suppresses proliferation of human cervical carcinoma HeLa cells by targeting cyclin E1. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 30:597–600. 2014.(In Chinese). PubMed/NCBI
27	Li W, Jin X, Deng X, Zhang G, Zhang B and Ma L: The putative tumor suppressor microRNA-497 modulates gastric cancer cell proliferation and invasion by repressing eIF4E. Biochem Biophys Res Commun. 449:235–240. 2014. View Article : Google Scholar : PubMed/NCBI
28	Xie Y, Wei RR, Huang GL, Zhang MY, Yuan YF and Wang HY: Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma. Medical Oncology. 31:8442014. View Article : Google Scholar : PubMed/NCBI
29	Ohba T, Cates JM, Cole HA, Slosky DA, Haro H, Ando T, Schwartz HS and Schoenecker JG: Autocrine VEGF/VEGFR1 Signaling in a Subpopulation of Cells Associates with Aggressive Osteosarcoma. Molecular Cancer Research molcanres. 0037.2014. 2014. View Article : Google Scholar
30	Liu H, Huang L, Zhang Z, Zhang Z, Yu Z, Chen X, Chen Z, Zen Y, Yang D, Han Z, et al: LIM mineralization protein-1 inhibits the malignant phenotypes of human osteosarcoma cells. International journal of molecular sciences. 15:7037–7048. 2014. View Article : Google Scholar : PubMed/NCBI
31	He H, Ni J and Huang J: Molecular mechanisms of chemoresistance in osteosarcoma. Oncol Lett. 7:1352–1362. 2014.(Review). PubMed/NCBI
32	Zhang H, Yin Z, Ning K, Wang L, Guo R and Ji Z: Prognostic value of microRNA-223/epithelial cell transforming sequence 2 signaling in patients with osteosarcoma. Hum Pathol. 45:1430–1436. 2014. View Article : Google Scholar : PubMed/NCBI